Laurence Albiges, MD, PhD, and Toni K. Choueiri, MD, on Metastatic RCC: Perspectives on the Carmena Trial
2018 ASCO Annual MeetingToni K. Choueiri, MD, of Dana-Farber Cancer Institute, and Laurence Albiges, MD, PhD, of Gustave Roussy, discuss the implications of this study’s potentially practice-changing finding that nephrectomy is no longer the standard of care for patients with metastatic renal cell carcinoma (Abstract LBA3).
Related Videos
William G. Wierda, MD, PhD, and Julie M. Vose, MD, MBA, on CLL: Results From the CAPTIVATE Trial
Julie M. Vose, MD, MBA, of the University of Nebraska Medical Center, and William G. Wierda, MD, PhD, of The University of Texas MD Anderson Cancer Center, discuss...
Toni K. Choueiri, MD, and Lauren C. Harshman, MD on RCC: Results From the PROSPER Trial
Toni K. Choueiri, MD, and Lauren C. Harshman, MD, both of Dana-Farber Cancer Institute, discuss phase III study findings on perioperative nivolumab vs observation ...
Tony Mok, MD, on NSCLC: Results From the ARCHER 1050 Trial
Tony Mok, MD, of the Chinese University of Hong Kong, discusses study findings on dacomitinib vs gefitinib for first-line treatment of advanced non–small cell lung cancer, a final ...
Arnaud Méjean, MD, PhD, on RCC: Results From the Carmena Trial
Arnaud Méjean, MD, PhD, of the Hôpital Européen Georges Pompidou, discusses his study’s potentially practice-changing finding that nephrectomy is no longer the standard of care for...
Toni K. Choueiri, MD, and Jonathan E. Rosenberg, MD: Bladder Cancer Roundup
Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, and Jonathan E. Rosenberg, MD, of Memorial Sloan Kettering Cancer Center, discuss their perspectives on the ...
